Newly approved and emerging Kras G12C inhibitors can only benefit a small percentage of pancreatic cancer patients, and there are no approved drugs targeting the major PDAC mutations Kras G12D and G12V (25). This evidence concerns the gene KRAS and pancreatic neoplasm.